Expression of vascular endothelial growth factor-C and vascular endothelial growth factor receptor-3 in esophageal squamous cell carcinoma

Oncology Letters

Volumn 7, Issue 4, 2014, Pages 1027-1032

  Omoto, Itaru ^a   Matsumoto, Masataka ^a   Okumura, Hiroshi ^a   Uchikado, Yasuto ^a   Setoyama, Tetsuro ^a   Kita, Yoshiaki ^a   Owaki, Tetsuhiro ^a   Kijima, Yuko ^a   Shinchi, Hiroyuki ^a   Ishigami, Sumiya ^a   Ueno, Shinichi ^a   Natsugoe, Shoji ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Esophageal cancer; Microlymphatic vessel density; Vascular endothelial growth factor receptor 3; Vascular endothelial growth factor C

Indexed keywords

MONOCLONAL ANTIBODY D2-40; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CAPILLARY DENSITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SURVIVAL RATE; THORACOTOMY; TUMOR INVASION;

EID: 84896709372     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1823     Document Type: Article

References (37)

1. Daly JM, Fry WA, Little AG, et al: Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 190: 562-573, 2000.
2. Plate K: From angiogenesis to lymphangiogenesis. Nat Med 7: 151-152, 2001.
3. Dumont DJ, Jussila L, Taipale J, et al: Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282: 946-949, 1998.
4. Joukov V, Pajusola K, Kaipainen A, et al: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. Embo J 15: 290-298, 1996.
5. Jeltsch M, Kaipainen A, Joukov V, et al: Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276: 1423-1425, 1997.
6. Su JL, Yang PC, Shih JY, et al: The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 9: 209-223, 2006.
7. Su JL, Yen CJ, Chen PS, et al: The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 96: 541-545, 2007.
8. Su JL, Chen PS, Chien MH, et al: Further evidence for expression and function of the VEGF-C/VEGFR-3 axis in cancer cells. Cancer Cell 13: 557-560, 2008.
9. Kitadai Y, Amioka T, Haruma K, et al: Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer 93: 662-666, 2001.
10. Arigami T, Natsugoe S, Uenosono Y, et al: Lymphatic invasion using D2-40 monoclonal antibody and its relationship to lymph node micrometastasis in pN0 gastric cancer. Br J Cancer 93: 688-693, 2005.
11. Han FH, Li HM, Zheng DH, He YL and Zhan WH: The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol 36: 1172-1179.
12. Kodama M, Kitadai Y, Tanaka M, et al: Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms. Clin Cancer Res 14: 7205-7214, 2008.
13. Witte D, Thomas A, Ali N, Carlson N and Younes M: Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res 22: 1463-1466, 2002.
14. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T and Uchida Y: Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 97: 457-464, 2003.
15. Botting SK, Fouad H, Elwell K, et al: Prognostic significance of peritumoral lymphatic vessel density and vascular endothelial growth factor receptor 3 in invasive squamous cell cervical cancer. Transl Oncol 3: 170-175, 2010.
16. Van Trappen PO, Steele D, Lowe DG, et al: Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 201: 544-554, 2003.
17. Li R, Younes M, Wheeler TM, et al: Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate 58: 193-199, 2004.
18. Jennbacken K, Vallbo C, Wang W and Damber JE: Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 65: 110-116, 2005.
19. Sobin LH, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumours, 7th Edition. International Union Against Cancer 2009.
20. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
21. Liang P, Hong JW, Ubukata H, et al: Increased density and diameter of lymphatic microvessels correlate with lymph node metastasis in early stage invasive colorectal carcinoma. Virchows Arch 448: 570-575, 2006.
22. Tomita N, Matsumoto T, Hayashi T, et al: Lymphatic invasion according to D2-40 immunostaining is a strong predictor of nodal metastasis in superficial squamous cell carcinoma of the esophagus: algorithm for risk of nodal metastasis based on lymphatic invasion. Pathol Int 58: 282-287, 2008.
23. Liu B, Ma J, Wang X, et al: Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma. Anat Rec (Hoboken) 291: 1227-1235, 2008.
24. Saad RS, Lindner JL, Liu Y and Silverman JF: Lymphatic vessel density as prognostic marker in esophageal adenocarcinoma. Am J Clin Pathol 131: 92-98, 2009.
25. Zhou M, He L, Zu X, Zhang H, Zeng H and Qi L: Lymphatic vessel density as a predictor of lymph node metastasis and its relationship with prognosis in urothelial carcinoma of the bladder. BJU Int 107: 1930-1935, 2011.
26. Skobe M, Hawighorst T, Jackson DG, et al: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7: 192-198, 2001.
27. Podgrabinska S, Braun P, Velasco P, Kloos B, Pepper MS and Skobe M: Molecular characterization of lymphatic endothelial cells. Proc Natl Acad Sci USA 99: 16069-16074, 2002.
28. Wissmann C and Detmar M: Pathways targeting tumor lymphangiogenesis. Clin Cancer Res 12: 6865-6868, 2006.
29. Hirakawa S: From tumor lymphangiogenesis to lymphvascular niche. Cancer Sci 100: 983-989, 2009.
30. Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997.
31. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611, 2004.
32. Ordonez NG: D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 36: 372-380, 2005.
33. Franchi A, Gallo O, Massi D, Baroni G and Santucci M: Tumor lymphangiogenesis in head and neck squamous cell carcinoma: a morphometric study with clinical correlations. Cancer 101: 973-978, 2004.
34. Yonemura Y, Endou Y, Sasaki T, et al: Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol 36: 1131-1138, 2010.
35. Burton JB, Priceman SJ, Sung JL, et al: Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res 68: 7828-7837, 2008.
36. Mumprecht V, Honer M, Vigl B, et al: In vivo imaging of inflammation-and tumor-induced lymph node lymphangiogenesis by immuno-positron emission tomography. Cancer Res 70: 8842-8851, 2010.
37. Zehnder-Fjällman AH, Marty C, Halin C, et al: Evaluation of anti-VEGFR-3 specific scFv antibodies as potential therapeutic and diagnostic tools for tumor lymph-angiogenesis. Oncol Rep 18: 933-941, 2007.